Allogeneic transplantation after reduced-intensity conditioning with fludarabine-CY for both indolent and aggressive lymphoid malignancies

Bone Marrow Transplantation

Volumn 49, Issue 4, 2014, Pages 513-518

  Wondergem, M J ^a   Dijkstra, F S ^a   Visser, O J ^a   Zweegman, S ^a   Ossenkoppele, G J ^a   Witte, B I ^a   Janssen, J J W M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aggressive; Allogeneic; Indolent; Lymphoma

Indexed keywords

CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENETICILLIN; RITUXIMAB; STEROID; VALACICLOVIR; ANTINEOPLASTIC AGENT; VIDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOTRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; B CELL LEUKEMIA; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; EVENT FREE SURVIVAL; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INCIDENCE; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; UNRELATED DONORS; VERY ELDERLY; ANALOGS AND DERIVATIVES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 84897522776     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.221     Document Type: Article

References (27)

1. van Besien K, Loberiza FR, Bajorunaite R, Armitage JO, Bashey A, Burns LJ et al. Comparison of autologous and allogeneic haematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521-3529.
2. Dann EJ, Daugherty CK, Larson RA. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. Bone Marrow Transplant 1997; 20: 369-374.
3. Khouri IF, Saliba RM, Giralt SA. Nonablative allogeneic haematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-vs-host disease, and treatment-related mortality. Blood 2001; 98: 3595-3599.
4. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft versus tumor effects. Blood 2001; 97: 3390-3400.
5. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316-2323.
6. Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Poplewel L et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood and Marrow Transplant 2006; 12: 1326-1334.
7. Bertz H, Illerhaus G, Veelken H, Finke J. Allogeneic hematopoetic stem cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reducedintensity regimens. Ann Oncol 2002; 13: 135-139.
8. Toze C, Barnett MJ. Allogeneic haemopoietic stem cell transplantation for non- Hodgkin's lymphoma. Best Pract Res Clin Haematol 2002; 15: 481-504.
9. Thomson KJ, Morris EC, Bloor A, Cook G, Milligan D, Parker A et al. Favourable long term survival after reduced-intensity alloSCT for multiple-relapse aggressive NHL. J Clin Oncol 2008; 27: 426-432.
10. Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation in relapsed, refractory and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 211-217.
11. Barrett AJ, Savani BN. Stem cell transplantation with reduced intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006; 20: 1661-1672.
12. Przepiorka D. Consensus conference on acute GvHD. Bone Marrow Transplant 1995; 15: 825-828.
13. Lee SJ, Vogelsang G, Flowers MED. Chronic graft versus host disease. Biol Blood Marrow Transplant 2003; 9: 215-233.
14. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russel N, Ruiz de Elvira C et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation; an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310-4316.
15. Hamadani M, Benson DM, Hofmeister CC, Elder P, Blum W, Porcu P et al. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. Biol Blood Marrow Transplant 2009; 15: 547-553.
16. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation for relapsed and refractory non-hodgkin lymphoma. Blood 2004; 104: 3865-3871.
17. Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R. Outcomes after allogeneic hematopoietic cell transplantation with non myeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008; 111: 446-452.
18. Armand P, Kim HT, Ho VT. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14: 418-425.
19. Thomson KJ, Morris EC, Bloor A, Cook G, Milligan D, Parker A et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008; 27: 426-432.
20. van Kampen RJW, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after autologous stem cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29: 1342-1348.
21. Vellenga E, van Putten WJ, van't Veer MB, Zijlstra JM, Fibbe WE, van Oers MHJ et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008; 111: 537-543.
22. Pidala J, Anasetti C, Jim H. Quality of life after allogeneic stem cell transplantation. Blood 2009; 114: 7-19.
23. Gisselbrecht C. Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma? Hematology Am Soc Hematol Educ Program 2012; 2012: 410-416.
24. Bloor AJ, Thomson K, Chowdry N, Verfuerth S, Ings SJ, Chakraverty R et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 50-58.
25. Maloney DG. Graft-vs-lymphoma effect in various histologies of non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: 99-105.
26. Avivi I, Goldstone AH. Conventional allograft and autograft in low grade lymphoma. Best Pract Res Clin Haematol 2005; 18: 113-128.
27. Thepot S, Zhou J, Perrot A, Robin M, Xhaard A, de Latour RP et al. The graft-versusleukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia 2010; 24: 1852-1858.